1. Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
- Author
-
Xiaolei Zhou, Gema Sanz Santos, Yue Zhan, Mariana M. S. Oliveira, Shiva Rezaei, Madhurendra Singh, Sylvain Peuget, Lisa S. Westerberg, John Inge Johnsen, and Galina Selivanova
- Subjects
Inflammation ,Mice ,Cancer Research ,Oncology ,Gain of Function Mutation ,Neoplasms ,Tumor Microenvironment ,Animals ,Interferons ,Tumor Suppressor Protein p53 - Abstract
Backgroundp53 mutants contribute to the chronic inflammatory tumour microenvironment (TME). In this study, we address the mechanism of how p53 mutants lead to chronic inflammation in tumours and how to transform it to restore cancer immune surveillance.MethodsOur analysis of RNA-seq data from The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) project revealed that mutant p53 (mtp53) cancers correlated with chronic inflammation. We used cell-based assays and a mouse model to discover a novel gain of function of mtp53 and the effect of the mtp53 reactivating compound APR-246 on the anti-tumour immune response.ResultsWe found that tumour samples from patients with breast carcinoma carrying mtp53 showed elevated Interferon (IFN) signalling,TumourInflammationSignature (TIS) score and infiltration of CD8+ T cells compared to wild type p53 (wtp53) tumours. We showed that the expression of IFN and immune checkpoints were elevated in tumour cells in a mtp53-dependent manner, suggesting a novel gain of function. Restoration of wt function to mtp53 by APR-246 induced the expression of endogenous retroviruses, IFN signalling and repressed immune checkpoints. Moreover, APR-246 promoted CD4+ T cells infiltration and IFN signalling and prevented CD8+ T cells exhaustion within the TME in vivo.ConclusionsBreast carcinomas with mtp53 displayed enhanced inflammation. APR-246 boosted the interferon response or represses immune checkpoints in p53 mutant tumour cells, and restores cancer immune surveillance in vivo.
- Published
- 2022
- Full Text
- View/download PDF